Treatment of patients with pericarditis with anti-inflammatory drugs

Eight years have passed since the update of the European recommendations for the management of pericarditis [1], and the pandemic of the new coronavirus continues for about 3 years of the period. It has changed the structure and course of all cardiovascular diseases. At present, there is no doubt that a new coronavirus SARS-CоV-2 is the dominant cause of pericarditis. However, such non-infectious causes as systemic inflammatory diseases, paraneoplasic diseases and postpericardiotomy syndromes remain relevant, and require a differentiated therapeutic strategy. For a better understanding of the parameters for a treatment regimen choice, a systematic review considers the pathogenesis of pericarditis development, taking into account modern ideas about infectious and immune mechanisms, as well as a high probability of SARS-CоV-2 virus combination with all the other existing causes. Particular attention is paid to publications on the diagnosis in pandemic conditions, and the effectiveness of pericarditis therapy regimens for inflammation of the heart structures associated with COVID-19. A literature review has been carried out with the use of the medical resources PubMed, Google Scholar, UpToDate, including publications dated from 01.1990 to 09.2022, and concerning the issues of differentiated therapy of pericarditis with various anti-inflammatory drugs.